Board of Directors

Douglas A. Michels has served as our Chairman of the board since March 2022. Mr. Michels, who has served on TYME’s Board of Directors since October 2018, has over 39 years of experience in the healthcare industry. Most recently, he served as President and Chief Executive Officer of OraSure Technologies, Inc. Prior to OraSure, Mr. Michels spent 19 years with Johnson & Johnson in a range of executive positions, including as President of Ortho Clinical Diagnostics International and President of Johnson & Johnson Healthcare Systems. He currently serves on the Board of Directors of West Pharmaceutical Services, Inc. (NYSE:WST). In February 2010, Mr. Michels was appointed to the Presidential Advisory Council on HIV/AIDS by President Barack Obama.

Christine D. Baker has served as member of our board of directors since March 2022. Ms. Baker brings over 30 years of experience in the biotech/pharmaceutical industry, with expertise in business development, commercialization, and drug development strategies. She is currently the Chief Operating Officer of Hookipa Pharma, a public, clinical-stage biotechnology company. Ms. Baker joined Hookipa in 2019 as Chief Business Officer. Prior to this, she provided commercial development consulting services to biotech companies as the principal of CD Baker Consulting and was also the Chief Business Officer of EpicentRX, a privately held clinical-stage biotechnology company. Ms. Baker also held several management positions at Novartis Pharmaceuticals Corporation, including Vice President and Executive Director, Oncology Early Commercial Strategy. She began her career at Schering-Plough, where she advanced through a variety of roles in R&D, Marketing and Sales, Business Development, and General Management. Ms. Baker holds a degree in Chemistry from Dartmouth College and an MBA from Rutgers University.

David Carberry has served as a member of our board of directors since 2017. Mr. Carberry has over 40 years of experience in the healthcare industry as a financial executive. From 2012 to 2016, Mr. Carberry was the Chief Financial Officer of Excellis Health Solutions, LLC, a consulting and software solutions company focused on the healthcare industry. From 2008 to 2010, Mr. Carberry was Chief Financial Officer of Aldagen, a biopharmaceutical company. From 1981 to 2008, Mr. Carberry served in a number of financial oversight roles within Johnson & Johnson, including Vice President, Finance of Independence Technology L.L.C., Johnson & Johnson/Merck Consumer Pharmaceuticals, and Vice President, Finance of Johnson Health Care Systems, Inc., a healthcare account management and business services provider. Mr. Carberry received a Bachelor of Science degree in Accounting from La Salle University and Master in Business Administration in Finance from Drexel University. Mr. Carberry is a Certified Management Accountant.

Don DeGolyer has served as a member of our board of directors since May 2018. Mr. DeGolyer has over 30 years of experience in the pharmaceutical industry. Mr. DeGolyer currently serves on the board of directors of HLS Therapeutics, Inc., a specialty pharmaceutical company. He is also the Founder and Chief Executive Officer of Vertice Pharma, LLC, as well as a member of its board of directors. From 2013 to 2015, Mr. DeGolyer served as Chief Operating Officer of Endo Pharmaceuticals. Prior to Endo, he served as President & CEO of Sandoz North America. Mr. DeGolyer also held various leadership roles at Pfizer, Johnson & Johnson and Novartis. Mr. DeGoyler received a Bachelor of Science degree from University of Rochester and a Master in Business Administration from Fairleigh Dickinson University.r

Mr. Cunningham is our Chief Executive Officer as of November 2020 and brings more than 20 years of successful leadership experience spanning from pre-IND drug discovery through the commercialization and launch of over a dozen therapies in oncology, rare disease, infectious disease, respiratory, neurology, cardiovascular and metabolic diseases. Richie brings to TYME an in-depth understanding of maximizing therapeutic lifecycles, enhancing efficiencies and outcomes in biotech business models, and most importantly a commitment to a value driven culture.

Mr. Cunningham also brings significant experience in mergers & acquisitions, business development, strategy development, therapeutic launches, contracting, managed care, and sales & marketing. Most recently, Richie served as CEO at Icagen, leading the company through two transformational acquisitions, acquiring assets and talent out of Pfizer and Sanofi. While CEO at Icagen, he successfully negotiated and signed multiple licensing deals with Roche, Sanofi and the Cystic Fibrosis Foundation.

Prior to joining Icagen, Mr. Cunningham was an executive with one of the world’s largest pharmaceutical companies, Boehringer Ingelheim, where he held a variety of key strategic and operational roles, including the launch of Boehringer’s first entrance into the oncology market with Gilotrif® (afatinib), an oral tyrosine kinase inhibitor, as a treatment for patients with non-small cell lung cancer.

Steve Hoffman co-founded TYME and served as our Chairman of the board and Chief Science Officer from November 2020 to March 2022. Steve served as our Chief Executive Officer from March 2015 to November 2020. Mr. Hoffman has over 30 years of experience in biochemistry and physics and has been the lead author on over 40 patents. For the last decade, he has focused on biopharmaceuticals for oncology, metabolic syndrome, and central nervous system disorders. Prior to working in biotech, he was involved in projects related to chemistry, aerospace, and laser optics. In addition to leading the scientific development for his own companies, he has worked with multiple Fortune 500 healthcare companies, academic institutions, and the US government.

Gerald H. Sokol has served as a member of our board of directors since 2014. For 27 years Dr. Sokol served on the review staff of the Food and Drug Administration as a senior regulatory scientist and officer composing over 300 white papers, IND and NDA reviews, and opinion papers. Dr. Sokol attained his medical degree from Indiana University’s Combined Degree Program in Experimental Medicine with a Master of Science in Pharmacology and an MD. Dr. Sokol interned in Medicine at Temple University and attended the US Public Health Service Hospital in affiliation with the National Cancer Institute, Johns Hopkins, and the University of Maryland completing training in Internal Medicine. He then completed training at the Massachusetts General Hospital, Harvard Medical School in Radiation Oncology, Medical Oncology and Clinical Pharmacology attaining Board Certification in Internal Medicine, Medical Oncology, Radiation Oncology, Clinical Pharmacology, and later Quality Assurance and Utilization Review. He is also certified in Skin Cancer Medicine from the University of Queensland. Dr. Sokol is currently Chief of Radiation Oncology at the University of South Florida’s Tampa General Hospital and is a board member and partner of Florida Cancer Specialists and Research Institute. Dr. Sokol currently holds professorships in Medicine and Pharmacology at the Uniform Services University. Dr. Sokol is a lifetime fellow and board member of the American Cancer Society and a fellow of the American College of Clinical Pharmacology.

Timothy C. Tyson has served as a member of our board of directors since 2015. Mr. Tyson has over 35 years of experience in the pharmaceutical industry. He currently serves as Chairman of Icagen Inc. Mr. Tyson has held numerous executive level positions at various pharmaceutical companies including Chairman and Chief Executive Officer of Avara Pharmaceutical Services, Inc., Chairman and Chief Executive Officer of Aptuit LLC, Chief Executive Officer, Chief Operating Officer and President of Valeant Pharmaceuticals International, President of Global Manufacturing and Supply for GlaxoSmithKline and ran Glaxo Dermatology and Cerenex Pharmaceuticals, and held executive positions at Bristol-Myers Squibb and Proctor and Gamble. Mr. Tyson has served on the board of directors of Valeant Pharmaceuticals International, The Pharmaceutical Research and Manufacturing Association, BICOM, the Chief Executive Officer Roundtable for the University of California at Irvine, the Dean’s Executive Forum at Cal State Fullerton, the Health Sector Advisory Board at Duke University, the International Leadership Forum of the International Society of Pharmaceutical Engineers and as a visiting lecturer at Cambridge University. Mr. Tyson received a Master in Business Administration and a Master of Science degree in Public Administration from Jacksonville State University. Mr. Tyson is also a graduate of the United States Military Academy at West Point.